{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:03:48Z","timestamp":1784325828435,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Labelled Comp Radiopharmac"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Vanin\u20101 is an enzyme highly expressed in the kidneys, liver, and small intestines. Inhibition of this enzyme has been postulated as a novel approach in the treatment of several inflammatory diseases.\n                    <jats:bold>BI 764122<\/jats:bold>\n                    ,\n                    <jats:bold>BI 1585773<\/jats:bold>\n                    , and\n                    <jats:bold>BI 1595043<\/jats:bold>\n                    are very potent inhibitors of this enzyme. These three analogs share the same (\n                    <jats:italic>S<\/jats:italic>\n                    )\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010(nicotinoyl)pyrrolidin\u20103\u2010yl)\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010methyl acetamide moiety. The preparation of these analogs labelled with carbon\u201014 was accomplished via carbon\u201014 carboxylation with carbon dioxide of corresponding aryl halides, followed by amide bond formation with (\n                    <jats:italic>S<\/jats:italic>\n                    )\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010(methyl)\u2010\n                    <jats:italic>N\u2010<\/jats:italic>\n                    (pyrrolidin\u20103\u2010yl)acetamide. For metabolic considerations, the radioactive carbon was also incorporated in a cyclopropyl in [\n                    <jats:sup>\n                      <jats:bold>14<\/jats:bold>\n                    <\/jats:sup>\n                    <jats:bold>C<\/jats:bold>\n                    ]\n                    <jats:bold>\u2010BI 764122<\/jats:bold>\n                    synthesis. The deuterium labelling of these three compounds was completed using the common moiety (\n                    <jats:italic>S<\/jats:italic>\n                    )\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010(methyl\u2010\n                    <jats:italic>d<\/jats:italic>\n                    <jats:sub>3<\/jats:sub>\n                    )\u2010\n                    <jats:italic>N<\/jats:italic>\n                    \u2010(pyrrolidin\u20103\u2010yl)acetamide\u2010\n                    <jats:italic>d<\/jats:italic>\n                    <jats:sub>3<\/jats:sub>\n                    , which was prepared in three steps and then coupled to the corresponding aryl acids via amide bond.\n                  <\/jats:p>","DOI":"10.1002\/jlcr.70033","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:25:18Z","timestamp":1783607118000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthesis of Potent Vanin\u20101 Inhibitors Labelled With Carbon\u201014 and Deuterium"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-9792","authenticated-orcid":false,"given":"Bachir","family":"Latli","sequence":"first","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Hrapchak","sequence":"additional","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalith","family":"Samankumara","sequence":"additional","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-4828","authenticated-orcid":false,"given":"Jaehee","family":"Lee","sequence":"additional","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-0108","authenticated-orcid":false,"given":"Bo","family":"Qu","sequence":"additional","affiliation":[{"name":"The Radiosynthesis Laboratory, Chemical Development Boehringer Ingelheim Pharmaceuticals, Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074\u20107613(00)80496\u20103"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.09.046"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.11.099"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255\u2010024\u201001059\u2010y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014\u20105793(00)02110\u20104"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064\u2010007\u20109486\u20107"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.16.7214\u20107224.2004"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.07.011"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.67"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21031"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039106"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20163891"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X241240428"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201009\u2010304931"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep21906"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176220"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70274"},{"key":"e_1_2_9_19_1","volume-title":"Heteroaromatic compounds as Vanin inhibitors","author":"Bosanac T.","year":"2018"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70285"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00231"},{"key":"e_1_2_9_22_1","volume-title":"Heteroaromatic compounds as vanin inhibitors","author":"Fleck M. M.","year":"2020"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100033\u20101339107"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22111952"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.2c00221"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00706\u2010011\u20100635\u2010y"}],"container-title":["Journal of Labelled Compounds and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jlcr.70033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jlcr.70033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jlcr.70033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:25:39Z","timestamp":1784323539000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jlcr.70033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/jlcr.70033"],"URL":"https:\/\/doi.org\/10.1002\/jlcr.70033","archive":["Portico"],"relation":{},"ISSN":["0362-4803","1099-1344"],"issn-type":[{"value":"0362-4803","type":"print"},{"value":"1099-1344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70033"}}